IKB alpha peptide

GeneTex

IKB alpha peptide

9

Intended for use as a control peptide when used with anti-IkB alpha (C-terminal specific ab GTX27545) to block specific interaction of anti-IkB alpha (C-terminal specific) with the IkB alpha subunit. Control peptide should be used at 1.0 mg per 1.0 ml of antiserum per assay.

Neutralisation/Blocking

Research Use Only

1 mg/ml

NFKBIA

NFKB inhibitor alpha

EDAID2, IKBA, MAD-3, NFKBI, NF-kappa-B inhibitor alpha, I-kappa-B-alpha, IkappaBalpha, ikB-alpha, major histocompatibility complex enhancer-binding protein MAD3, nuclear factor of kappa light chain gene enhancer in B-cells, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

Three major forms of IkB-like molecules have been identified and each is characterized by multiple copies of ankyrin repeats. IkB-alpha and IkB-beta appear to be the major regulatory forms of IkB in most cells. These proteins interact with p65 or c-Rel containing forms of NFkB and block nuclear import by masking the nuclear localization sequences of NFkB. The activation of NFkB involves the inducible phosphorylation and subsequent degradation of IkB. Immunoblotting easily detects the hyper-phosphorylated forms of IkB-alpha, but not phosphorylated IkB-beta. Interestingly, IkB-alpha and IkB-beta mediate different NFkB responses. IkB-alpha appears to control more transient activation of NFkB in response to an inducer, while IkB-beta controls a persistent response. Bcl-3 interacts with p50 and p52 containing forms of NFkB, but rather than being an inhibitor it appears to function to stimulate transcription. The degradation of IkB is confirmed by immunoblotting.

-20°C,2°C to 8°C

41116100

Human